3M patch tech under assessment for osteoporosis drug delivey

- Last updated on GMT

3M patch tech under assessment in osteoporosis
A transdermal patch technology developed by 3M Drug Delivery could lead to new injection free, compliance-boosting treatments for postmenopausal osteoporosis.

Massachusetts, US based biopharma Radius Health has started a Phase II trial of BA058 - peptide analog of human Parathyroid Hormone related Peptide (hPTHrP) – that uses 3M’s Microstructured Transdermal System microneedle technology.

Part of the rational for the research is to compare how well the delivery tech – which is designed to be worn for just a few minutes – with the same drug administrated via subcutaneous injection.

Radius CEO Michael Wyzga said: "The short wear-time transdermal delivery, based on 3M's technology, is intended to improve patient compliance and ease of use, and could potentially grow the opportunity in treating osteoporosis -- an underserved market."

"Our Phase 2 data for BA058-Injection (BA058-SC) demonstrates strong clinical evidence of bone-building capability, and with the initiation of this BA058-Transdermal (BA058-TD) trial, we seek to translate these results into a next generation transdermal formulation for the broader market​."

And previous research suggests the microneedles could be effective. Investigator Paul Miller from the University of Colorado Health Sciences Center, said: "In a Phase 1b study, BA058-TD showed that with a short wear-time of five minutes, peak drug levels were consistent with subcutaneous injection​."

3M has been working with Radius since 2011​ when the firms partnered to develop the formulations and production processes needed to deliver BA058 through the skin using the patch system.

At the time 3M told in-Pharmatechnologist.com that the Radius collaboration is one of a number of microneedle-focused projects it is involved in at the moment.

Related topics: Delivery technologies, Drug Delivery

Related news

Show more

Related products

Related suppliers